In prostate cancer, TDEVs increase CXCL12 production in bone marrow stromal cells (BMSCs) by transmitting PKM2, creating a microenvironment conducive to tumor cell engraftment (Dai et al., 2019). This evidence concerns the gene CXCL12 and prostate cancer.